The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
Official Title: A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Study ID: NCT03847519
Brief Summary: A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Detailed Description: To evaluate the safety and tolerability of ADXS-503, administered as monotherapy in Part A and in combination with pembrolizumab in Part B, and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD). As well, to characterize the preliminary anti-tumor activity of ADXS-503, administered in combination with pembrolizumab in Part C, per RECIST v1.1.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope, Duarte, California, United States
University of California, Los Angeles, Los Angeles, California, United States
Emory University, Atlanta, Georgia, United States
Illinois CancerCare, P.C., Peoria, Illinois, United States
The University of Kansas Medical Center, Westwood, Kansas, United States
Atlantic Health System, Carol G Simon Cancer Center, Morristown, New Jersey, United States
Montefiore Medical Center, Bronx, New York, United States
Providence Cancer Institute, Portland, Oregon, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Name: Surya Vangala
Affiliation: Senior Director, Clinical Operations, Advaxis Inc
Role: STUDY_DIRECTOR